

28th April 2005



Maelor plc Appoints Geoffrey McMillan as Non-Executive Director

Maelor plc, the specialist healthcare products company, today announced the appointment of Geoffrey McMillan as a Non-Executive Director with effect from 1st May, 2005.

Mr McMillan is currently the Chief Executive Officer of BioFocus plc, and has led the transition of that company from a founder-based service company to an integrated and profitable provider of drug discovery products, services and programmes. He had previously held Board positions at Roche, Xenova and Elan.

Alastair Macpherson, Chairman of Maelor plc, said: "Geoff's exceptional experience within the pharmaceutical and biotechnology sectors, particularly in product licensing and mergers and acquisitions, will provide us with a valuable insight in key strategic areas for Maelor. He strengthens the Board at an important point in Maelor's development when we are reaping the rewards of our investment in R+D, and looking forward to our current portfolio of products delivering profitability."

Directorship Details: Henry Geoffrey McMillan, aged 48, currently holds and has held directorships, during the five years preceding the date of this announcement as follows:

Current

BioFocus plc

Past

Elan Pharma International Ltd (Ireland)
Elan Pharma (Ireland) Ltd
Elan Pharma GmbH (Germany)
Elan Pharma AB (Sweden)
Elan Pharma Italy
Elan Pharma France
Elan Pharmaceutical Corporation (Philippines)
Vita Elan (Spain)
Manga Holdings (Spain)

There are no further disclosures to be made in accordance with Schedule 2 (f) of the AIM Rules.

-ends-

For further information:

Maelor plc	Stephen Appelbee, Chief Executive Officer	Tel: 01978 810 153
Financial Dynamics	Ben Atwell / Lucy Briggs	Tel: 0207 831 3113

Notes to editors:

Maelor plc

Maelor is an AiM-listed specialist healthcare products company. The company has several products on the market including OptiFlo®, ContiSol and Volplex.

OptiFlo, a urethral catheter maintenance range, launched in the UK in June 1999 and distributed through Bard Limited, has gained a 45% share of the UK community prescription market (source: IMS, February 2005).

ContiSol, Maelor's own-brand urethral catheter maintenance range, has already been launched in Spain (by CAIR España SL) and in Greece (by M. S. Jacovides SA). The product has also gained approval in Canada where the recently appointed distributor American Australian Medical, Inc., will be launching shortly.

Volplex, the company's blood plasma volume substitute, is used for patients suffering from the effects of trauma, surgery or certain medical conditions which result in hypovolaemia (lower than normal blood volume). It is distributed in the UK by Cambridge Laboratories Ltd, and in Argentina by Ahimsa SA.

Maelor has various products under development including micelle propofol, a reformulation of the world's biggest-selling general anaesthetic.

*Volplex® and ContiSol™ are trademarks of Maelor Pharmaceuticals Limited
OptiFlo® is a trademark of Bard Limited*